2021, Number 3
Mucormycosis: a challenge for medicine still in the 21st century
Language: Spanish
References: 7
Page: 95-96
PDF size: 173.02 Kb.
Text Extraction
No abstract.REFERENCES
Cornely, O.A., Alastruey-Izquierdo, A., Arenz, D., Chen, S.C.A., Dannaoui, E., Hochhegger, B., Hoenigl, M., Jensen, H.E. et al., “Mucormycosis ecmm msg Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium”, Lancet Infect Dis, 2019, 19: e405-e421.
Trobisch, A., Marterer, R., Gorkiewicz, G., Flaschberger, S., Lackner, H., Seidel, M., Sperl, D., Karastaneva, A., Kohlmaier, B., Egger, M., Urban, C., Benesch, M. y Strenger, V., “Invasive mucormycosis during treatment for acute lymphoblastic leukaemia: successful management of two life-threatening diseases”, Support Care Cancer, 2020, 28: 2157-2161.
Cornu, M., Bruno, B., Loridant, S., Navarin, P., François, N., Lanternier, F., Amzallag-Bellenger, E., Dubos, F., Mazingue, F. y Sendid, B., “Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report”, bmc Pharmacol Toxicol, 2018, 19: 81.